Drug Profile
Surzebiclimab - BeiGene
Alternative Names: BGB-A425; Humanised IgG1-variant monoclonal antibody against TIM-3Latest Information Update: 13 Sep 2023
Price :
$50
*
At a glance
- Originator BeiGene
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; HAVCR2 protein inhibitors; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Solid tumours; Squamous cell cancer
Most Recent Events
- 21 Jul 2023 Phase-II clinical trials in Squamous cell cancer (Combination therapy, First-line therapy, Late-stage disease, Metastatic disease, Recurrent) in USA, Australia, China (IV) (NCT05909904)
- 21 Jul 2023 Phase-II clinical trials in Squamous cell cancer (First-line therapy, Metastatic disease, Late-stage disease, Recurrent, Combination therapy) in Taiwan (IV) (NCT05909904)
- 04 Nov 2021 Phase-II clinical trials in Solid tumours (Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Australia (Parenteral) before November 2021 (NCT03744468)